[ACS]
Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer
文献作者：Steve Avery; Jamie M. Buske; Doris Chen; Herman Chen; Xin Chen; Andrew R. Davidson; Jean-Nicolas Desrosiers; Hanqing Dong; Noalle Fellah; David F. Fernández; John Grosso; Lu Han; Teri Hochdorfer; Amber M. Johnson; Brian P. Jones; Maciej Kalinowski; Katherine D. Launer-Felty; Jorge Lopez; Teresa Makowski; Carolyn Mastriano; Truong N. Nguyen; Nitinchandra D. Patel; Zhihui Peng; Tyler Potter; Robert P. Pritchard; Anil M. Rane; Max Reeve; Margaret C. Richins; Chase A. Salazar; John J. Salisbury; Robert Simpson; Liza Tabshey; Erin J. Tweed; Paul G. Wahome; Nancy Walsh-Sayles; Jordan A. Willie; Ethan Wood
10
Unified OrganocatalyticEnantioselective Approachto Axially Chiral Spiranes and Alkylidenecycloalkanes
